← Leaderboards
John Thomas Leppert
Veterans Admin Palo Alto Health Care Sys
$1,120,906
Attributed
$1,474,514
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $335.3K · FY2010–25$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,474,514 · 3
VA$0 · 2
By mechanism
K23$767,298 · 1
R21$707,216 · 2
I01$0 · 2
Top collaborators
- Alan C Pao5 shared
- Wendy Jane Fantl2 shared
- Dean W Felsher2 shared
Most similar at Veterans Admin Palo Alto Health Care Sys
Same institution · by research overlap
- Alan C Pao$1,483,550
- Catherine Mills Curtin$936,791
- Peter J. Bayley$1,601,912
- Ansgar J. Furst$0
- Joseph C Liao$11,013,084
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisVeteransBaseOperative Surgical ProceduresMalignant NeoplasmsDisorder RiskMorbidity - Disease RateCohortUrologicEventPositioning AttributeCaringHealthcare SystemsTumorProspectiveRenal CarcinomaRenal Cell CarcinomaComorbidityInnovationMedicalElectronic DataComplexPatternClinical Trials
Grant awards (18)
Defining Optimal Care for Urinary Stone Disease in the Veterans Health Administration$0
I01 · FY2025 · VA
Defining Optimal Care for Urinary Stone Disease in the Veterans Health Administration$0
I01 · FY2024 · VA
Defining Optimal Care for Urinary Stone Disease in the Veterans Health Administration$0
I01 · FY2023 · VA
Defining Optimal Care for Urinary Stone Disease in the Veterans Health Administration$0
I01 · FY2022 · VA
Personalized Life Expectancy to Encourage High Value Prostate Cancer Care$0
I01 · FY2021 · VA · contact PI
(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy$171,499
R21 · FY2020 · CA
Defining Optimal Care for Urinary Stone Disease in the Veterans Health Administration$0
I01 · FY2020 · VA
Personalized Life Expectancy to Encourage High Value Prostate Cancer Care$0
I01 · FY2020 · VA · contact PI
(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy$205,799
R21 · FY2019 · CA
Personalized Life Expectancy to Encourage High Value Prostate Cancer Care$0
I01 · FY2018 · VA · contact PI
Personalized Life Expectancy to Encourage High Value Prostate Cancer Care$0
I01 · FY2018 · VA · contact PI
Renal Morbidity Following Kidney Cancer Surgery$153,943
K23 · FY2014 · DK · contact PI
Renal Morbidity Following Kidney Cancer Surgery$153,943
K23 · FY2013 · DK · contact PI
Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal c$148,519
R21 · FY2013 · CA
Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal c$181,399
R21 · FY2012 · CA
Renal Morbidity Following Kidney Cancer Surgery$153,943
K23 · FY2012 · DK · contact PI
Renal Morbidity Following Kidney Cancer Surgery$153,400
K23 · FY2011 · DK · contact PI
Renal Morbidity Following Kidney Cancer Surgery$152,069
K23 · FY2010 · DK · contact PI